Cancer evolution plays a key role in both the development of tumors and their response to
therapy. Like all evolutionary processes, tumor evolution is shaped by the environment. In …

The tumor microenvironment (TME) is a complex and ever-changing “rogue organ”
composed of its own blood supply, lymphatic and nervous systems, stroma, immune cells …

Tumor microenvironment (TME) includes a wide range of cell types including cancer cells,
cells which are involved in stromal structure and immune cells (tumor suppressor and tumor …

Cancer divergence has many facets other than being considered a genetic term. It is a
tremendous challenge to understand the metastasis and therapy response in cancer …

Advances in our understanding of molecular mechanisms of tumorigenesis have translated
into knowledge-based therapies directed against specific oncogenic signaling targets …

Environment-mediated drug resistance is a form of de novo drug resistance that protects
tumour cells from the initial effects of diverse therapies. Surviving foci of residual disease …

The success of targeted therapies in cancer treatment has been impeded by various
mechanisms of resistance. Besides the acquisition of resistance-conferring genetic …

Cancer occurs in a complex tissue environment, and its progression depends largely on the
tumour microenvironment (TME). The TME has a highly complex and comprehensive system …

During development of a novel treatment for cancer patients, the tumor microenvironment
and its interaction with the tumor cells must be considered. Aspects such as the extracellular …

Therapeutic resistance continues to be an indominable foe in our ambition for curative
cancer treatment. Recent insights into the molecular determinants of acquired treatment …